Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of April 2023

Commission File Number: 001-37452

 

 

CELYAD ONCOLOGY SA

(Translation of registrant’s name into English)

 

 

Rue Edouard Belin 2

1435 Mont-Saint-Guibert, Belgium

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

 

 

 

---

Celyad Oncology SA

On April 4, 2023, Celyad Oncology SA (the “Company”) published the convening notice for the Ordinary General Meeting of Shareholders to be held on May 5, 2023, at 2:00 p.m. (Central European time). A copy of the convening notice is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In addition, on April 4, 2023, the Company published a special report in accordance with Article 7:228 of the Belgian Companies and Associations Code. A copy of the special report is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

The information contained in this Current Report on Form 6-K, including Exhibits 99.1 and 99.2, is hereby incorporated by reference into the Company’s Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File No. 333-220737).

EXHIBITS

 

Exhibit		Description
99.1		Convening notice issued by the registrant on April 4, 2023
99.2		Special report issued by the registrant on April 4, 2023

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

				CELYAD ONCOLOGY SA
Date: April 4, 2023				By:		/s/ Michel Lussier
						Michel Lussier
						Interim Chief Executive Officer